IQVIA Holdings Inc. ($IQV) Stock Forecast: Down 5.2% Today

What is IQVIA Holdings Inc.?

IQVIA Holdings Inc (IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the healthcare industry. The stock had a bearish movement today.

Why is IQVIA Holdings Inc. going down?

IQV stock is down 5.2% on Jun 18, 2026 15:06

• Despite a positive earnings forecast and analyst ratings, IQV's stock experienced a bearish trend, indicating potential profit-taking by investors.
• The strong shareholder structure and institutional holdings may not have been enough to offset broader market sentiment impacting IQV's stock price.
• It's possible that external factors, such as overall market volatility or sector rotation, contributed to the bearish movement in IQV's stock, overshadowing the positive forecasts and ratings.

IQV Price Chart

IQV Technical Analysis

IQV News

IQVIA Holdings Inc (IQV) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for IQVIA Holdings Inc (IQV), highlighting its strong earnings forecast score and analyst ratings. It details the average price target, revenue expectations for the next quarter, and past EPS performance. Twenty-five analysts currently rate IQV as a "Buy," with a target price of $254.00.

https://www.tradingkey.com/markets/stocks/nasdaq-iqv/earnings

Skye Bioscience Inc (SKYE) Earnings Forecast: Future EPS & Revenue Growth Estimates

Skye Bioscience Inc (SKYE) has an earnings forecast score of 8.00, placing it 163rd in the Biotechnology & Medical Research industry. Analysts have set an average price target of $10.00 for SKYE, with a range from $2.00 to $20.00. Most analysts rate SKYE as a "Buy," reflecting positive sentiment despite recent EPS being below market expectations.

https://www.tradingkey.com/markets/stocks/nasdaq-skye/earnings

IQVIA Holdings Inc (IQV) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of IQVIA Holdings Inc's (IQV) shareholder structure, listing its major individual shareholders and the proportion of shares they hold. It also categorizes shareholders by type, such as investment advisors and hedge funds, and tracks institutional shareholding changes over recent quarters. Additionally, the article identifies Exchange Traded Funds (ETFs) that hold IQVIA stock.

https://www.tradingkey.com/markets/stocks/nasdaq-iqv/ownership

Protagonist Therapeutics Inc (PTGX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Protagonist Therapeutics Inc (PTGX) has an earnings forecast score of 8.57, ranking 99th in the Biotechnology & Medical Research industry, with an average price target of $91.00. Based on 14 analysts, the stock has a "Buy" rating. The expected revenue for the next quarter is $213.37 million, and the EPS for the next quarter is projected to be $1.94, compared to a previous quarter's EPS of -$0.69.

https://www.tradingkey.com/markets/stocks/nasdaq-ptgx/earnings

PMV Pharmaceuticals Inc (PMVP) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for PMV Pharmaceuticals Inc (PMVP), including EPS and revenue growth estimates. Based on 5 analysts, the stock has a "Buy" rating with an average target price of $6.00, representing a significant upside. The article also details recent and forecasted EPS figures and provides a peer comparison.

https://www.tradingkey.com/markets/stocks/nasdaq-pmvp/earnings

Trending Today

CarMax Inc ($KMX) Stock Forecast: Up 5.2% Today

Chemours Company (The) ($CC) Stock Forecast: Down 5.4% Today

Celanese Corporation ($CE) Stock Forecast: Down 5.2% Today

Chegg Inc. ($CHGG) Stock Forecast: Down 5.9% Today

MicroVision Inc. ($MVIS) Stock Forecast: Down 6.5% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Down 5.2% Today

Freeport-McMoRan Inc. ($FCX) Stock Forecast: Down 5.0% Today

Litecoin ($LTC) Crypto Forecast: Down 5.1% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.3% Today

XRP ($XRP) Crypto Forecast: Down 5.7% Today

IQVIA Holdings Inc. Price History

06.03.2026 - IQV Stock was up 0.2%

• IQVIA Holdings Inc. (IQV) stock price saw a significant increase following the launch of the IQVIA.ai unified agentic AI platform in collaboration with Nvidia, aimed at enhancing operational efficiency and decision-making in the life sciences industry.
• The "Buy" rating upgrade from TD Cowen and the positive reception of the platform by top pharmaceutical companies contributed to investor optimism and drove the bullish movement in IQV's stock price.
• Aberdeen Group plc's substantial increase in stake in IQVIA Holdings Inc. and the company's strong Q4 earnings performance with exceeded EPS expectations and year-over-year revenue growth further bolstered investor confidence in IQV's future prospects.

23.03.2026 - IQV Stock was down 9.0%

• The bearish movement in IQV's stock today could be attributed to profit-taking by investors after a period of sustained growth.
• The positive news surrounding Royalty Pharma's dividend approval and partnership with Johnson & Johnson may have diverted some investor attention away from IQVIA Holdings Inc.
• The initiation of coverage by BMO Capital with an Outperform rating might have raised expectations for IQV's stock, leading to a sell-off as investors locked in profits.
• The Google Discover Core Update emphasizing personalized news feeds on IQVIA Holdings Inc. could have triggered algorithmic trading or increased volatility in the stock as investors digested the implications of the update.

04.05.2026 - IQV Stock was up 6.0%

• A recent price target adjustment and maintained Buy rating on IQV by HSBC indicate confidence in the company's long-term prospects, despite the revised target.
• IQVIA's plan to raise €950 million through senior notes to refinance debt highlights a strategic move to optimize its capital structure and enhance financial flexibility.
• The market responded positively to these recent developments, resulting in a bullish movement in IQV's stock as investors perceive the refinancing as a positive step towards long-term growth and innovation in the life sciences sector.

04.05.2026 - IQV Stock was up 6.1%

• IQVIA's decision to price senior notes due 2033 with a 4.625% interest rate is viewed as a strategic step to manage its existing debt more effectively, resonating well with investors.
• The successful pricing of the senior notes indicates a strong investor confidence in IQVIA's financial strategies and debt management capabilities.
• Despite HSBC revising the price target for IQVIA while upholding a Buy rating, the overall sentiment remains optimistic, contributing to the positive momentum in the company's stock.
• By opting to offer senior notes for refinancing purposes, IQVIA is displaying a proactive approach towards optimizing its capital structure, which could potentially bolster its long-term financial health and growth opportunities.

03.05.2026 - IQV Stock was down 5.2%

• A notable reduction in the price target from $240 to $210 by HSBC, despite affirming a Buy rating, may have triggered investor uncertainty and resultant stock selling pressure.
• IQVIA's subsidiaries' publicizing of senior notes offerings could have sparked worries about heightened debt levels and potential shareholder value dilution, contributing to the negative market sentiment.
• The company surpassed expectations in Q1 2026 earnings and revenue and bolstered partnerships. However, the perception of being undervalued according to InvestingPro analysis did not counterbalance the negative impact of the debt offerings on stock performance.
• The combined factors of a reduced price target, debt refinancing strategies, and market dynamics linked to the senior notes offerings likely played roles in today's decline in IQV's stock.

05.04.2026 - IQV Stock was up 10.0%

• IQVIA reported strong first-quarter 2026 financial results, with revenue increasing by 8.4% year-over-year to $4,151 million and Adjusted Diluted Earnings per Share up by 7.4%. This positive performance was driven by strong results in both Commercial Solutions and Research & Development Solutions.
• Despite exceeding earnings and revenue forecasts, the stock initially dipped in pre-market trading due to investor concerns. This could be attributed to market volatility and increased competition in the industry.
• IQVIA's strong performance was fueled by AI solutions, new drug launches, and strategic partnerships, along with aggressive share repurchases. The company's focus on innovation and growth strategies seems to be resonating well with investors, leading to a bullish market movement for the stock.

05.04.2026 - IQV Stock was up 5.2%

• IQVIA reported strong first-quarter 2026 financial results, exceeding revenue and earnings expectations, driven by robust performance in Commercial Solutions and Research & Development Solutions.
• Despite beating forecasts and reaffirming its full-year guidance, IQV's stock initially dipped in pre-market trading due to investor concerns, possibly related to market volatility and competition worries.
• The market movement turned bullish as investors likely recognized the company's strong fundamentals, including its AI solutions, new drug launches, and strategic partnerships, leading to a positive outlook for continued growth.
• Integration of AI in life sciences operations, as highlighted in industry reports, could have also positively influenced investor sentiment towards IQVIA, showcasing the company's innovative approach and potential for further advancements in the sector.

06.04.2026 - IQV Stock was up 11.2%

• IQVIA reported strong Q1 2026 financial results, with revenue reaching $4.15 billion, an 8.4% increase year-over-year, and EPS of $1.61, beating estimates.
• The stock surged by 9.60% on May 5, driven by the company's robust performance across its segments and exceeding earnings and revenue expectations.
• Analysts maintain a positive outlook on IQV, citing AI as a key driver for its success, despite some technical sell signals and debt concerns.
• The market responded positively to IQV's strong trading day, outperforming competitors and reflecting overall bullish sentiment towards the stock.

18.05.2026 - IQV Stock was down 5.2%

• Despite a positive earnings forecast and analyst ratings, IQV's stock experienced a bearish trend, indicating potential profit-taking by investors.
• The strong shareholder structure and institutional holdings may not have been enough to offset broader market sentiment impacting IQV's stock price.
• It's possible that external factors, such as overall market volatility or sector rotation, contributed to the bearish movement in IQV's stock, overshadowing the positive forecasts and ratings.

28.04.2026 - IQV Stock was up 7.5%

• IQVIA Holdings Inc. experienced a significant 5.7% surge in its stock price, outperforming its competitors and the broader market, indicating strong investor interest in the company.
• The bullish movement was part of a sector-wide rally in the diagnostics and research industry, with peers like Agilent Technologies and Thermo Fisher Scientific also posting notable gains.
• Analysts' bullish sentiments and positive outlook on IQVIA Holdings, citing factors such as expected revenue and earnings growth, a robust backlog, and strong demand driven by AI adoption, likely contributed to the stock's upward momentum.
• Investors should continue to monitor the sustainability of this rally and any further announcements from leading companies in the sector that could impact IQV's performance.

28.04.2026 - IQV Stock was up 5.5%

• IQVIA Holdings Inc. (IQV) stock outperformed its competitors and the broader market, breaking a four-day losing streak, fueled by strong trading activity.
• Analysts' bullish sentiments and optimistic price targets for IQV indicate confidence in the company's growth prospects, driven by factors such as strong demand from AI adoption and an active share repurchase program.
• The positive outlook for IQVIA Holdings Inc. (IQV) reflects investors' confidence in the company's revenue and earnings growth potential in the coming years, despite concerns about its weak liquidity profile and lack of dividend payments.

20.04.2026 - IQV Stock was down 5.7%

• The bearish movement in IQV's stock could be linked to CFRA downgrading its rating on the shares from Buy to Hold, potentially creating investor uncertainty and selling pressure.
• Despite IQVIA's strong Q1 earnings showing data strength and AI ambitions, the market reaction might have been influenced by the moderation in the stock rating, causing a shift in investor sentiment.
• The announcement of Labcorp's new AI-powered app for lab results interpretation could have negatively impacted IQV's stock, as investors may perceive increased competition or technological advancements in the healthcare data analytics field.
• IQVIA's decision to significantly increase its share repurchase program signals confidence in its financial health and future growth prospects, but the market might be reacting cautiously to this move amidst broader market uncertainties and the recent rating downgrade.